CD20-targeted therapy: the next generation of antibodies.
Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody (MoAb) rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse with the original disease. A better understanding of the mechanism of rituximab resistance has led to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 MoAbs and explains new strategies to overcome resistance.
van Meerten
Tom
T
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Hagenbeek
Anton
A
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000918:Antibody Specificity; D000920:Antibody-Dependent Cell Cytotoxicity; D018951:Antigens, CD20 / Q000187:drug effects* / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003167:Complement Activation; D016503:Drug Delivery Systems; D004351:Drug Resistance; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; C550338:PRO131921 monoclonal antibody; D011993:Recombinant Fusion Proteins; C540931:TRU-015 protein; D000069283:Rituximab; C533411:ocrelizumab; C493846:veltuzumab; C527517:ofatumumab; C550337:ocaratuzumab; C543332:obinutuzumab